Genmab A/S(Nasdaq: GMAB) announced today that the European Commission (EC) granted marketing authorization for TEPKINLY ® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R 2 ) ...
Key insight: Major changes in the federal student-loan program, authored by congressional Republicans and the Trump ...
A new study generated one of the most comprehensive spatially resolved transcriptomic maps of cellular communication between ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results